Accepted Manuscript

Title: Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method

Author: Heather J. Chalfin, Max Kates, Emma E. van der Toom, Stephanie Glavaris, James E. Verdone, Noah M. Hahn, Kenneth J. Pienta, Trinity J. Bivalacqua, Michael A. Gorin

PII: S0090-4295(18)30093-1
DOI: https://doi.org/10.1016/j.urology.2018.01.036
Reference: URL 20882

To appear in: *Urology*

Received date: 8-9-2017
Accepted date: 27-1-2018

Title: Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method

Heather J. Chalfin[1*], Max Kates[1*], Emma E. van der Toom[1,2], Stephanie Glavaris[1], James E. Verdone[1], Noah M. Hahn[1,3], Kenneth J. Pienta[1], Trinity J. Bivalacqua[1,3], Michael A. Gorin[1]

[*]The denoted authors contributed equally to this work

Affiliations:

[1]The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

[2]Department of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

[3]The Johns Hopkins University Greenberg Bladder Cancer Institute and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Correspondence:

Heather Chalfin, M.D.
600 N. Wolfe Street
Marburg 121
Baltimore, MD 21287
Email: heather.chalfin@jhmi.edu
Phone: (443)-742-3130
Fax: (410) 955-0833

Disclosure Statement: Author K.J.P. is a consultant for Celsee Diagnostic and is on the board of directors for Curis, Inc.

Acknowledgements & Funding: This work is supported by NCI grant nos. U54CA143803, CA163124, CA093900, CA143055 to K.J.P as well as the Prostate Cancer Foundation, the Patrick C. Walsh Fund, and a gift from the Stutt family. E.E.vdT is supported by the Cure for Cancer Foundation. H.J.C. is supported by the Urology Care Foundation's Resident Research Award.

Keywords: circulating tumor cells, bladder cancer, survival, EpCAM, cytokeratin

Abstract

Objective: To investigate circulating tumor cells (CTCs) as biomarkers of urothelial carcinoma (UC). The majority of this work to date has utilized the CellSearch test, which has limited sensitivity due to reliance on positive selection for the cell surface protein EpCAM.